Previous studies have indicated that p53 gene mutations were an uncommon event in acute lymphoblastic leukemia (ALL) in children. In one series of 330 patients, p53 mutations were seen in fewer than 3%. We analyzed bone marrow mononuclear cells derived from 10 children with ALL at diagnosis who subsequently failed to achieve a complete remission or who developed relapse within 6 months of attaining complete remission for p53 gene mutations and mdm-2 overexpression. We found that three children had p53 gene mutations, and four overexpressed mdm-2. Also, experiments comparing relative levels of mdm-2 RNA and protein in these patients demonstrated that mdm-2 overexpression HE DEVELOPMENT OF effective therapy for acute lymphoblastic leukemia (ALL) in children constitutes one of the major advances in oncology during the past 25 years. Currently about 70% to 75% of children are cured. Modern multiple drug induction regimens achieve complete remissions in 96% to 100% of patients.' Further improvements in these results may be made by identifying subsets of patients with resistant disease who require more intensive therapy including early bone marrow transplantation or more aggressive induction regimens.' Clinical markers have been used to define high, low, and intermediate risk groups. However, these have limitations because some patients with no adverse clinical or chromosomal markers do not respond to therapy.
Previous studies have indicated that p53 gene mutations were an uncommon event in acute lymphoblastic leukemia (ALL) in children. In one series of 330 patients, p53 mutations were seen in fewer than 3%. We analyzed bone marrow mononuclear cells derived from 10 children with ALL at diagnosis who subsequently failed to achieve a complete remission or who developed relapse within 6 months of attaining complete remission for p53 gene mutations and mdm-2 overexpression. We found that three children had p53 gene mutations, and four overexpressed mdm-2. Also, experiments comparing relative levels of mdm-2 RNA and protein in these patients demonstrated that mdm-2 overexpression HE DEVELOPMENT OF effective therapy for acute lymphoblastic leukemia (ALL) in children constitutes one of the major advances in oncology during the past 25 years. Currently about 70% to 75% of children are cured. Modern multiple drug induction regimens achieve complete remissions in 96% to 100% of patients.' Further improvements in these results may be made by identifying subsets of patients with resistant disease who require more intensive therapy including early bone marrow transplantation or more aggressive induction regimens.' Clinical markers have been used to define high, low, and intermediate risk groups. However, these have limitations because some patients with no adverse clinical or chromosomal markers do not respond to therapy.
Genetic factors are important in the etiology and outcome of pediatric ALL. Certain familial genetic disorders predispose to ALL; the incidence is increased in siblings and monozygotic twins. Chromosomal abnormalities are seen in 90% of cases, and many structural abnormalities appear to confer a worse prognosis.' There are a number of molecular alterations that have been found to correlate with outcome in childhood ALL. For example, chromosomal translocations leading to the E2A-PBXl, bcr-ab1 or MLL-AF4 fusion genes have been associated with a poor
In contrast, patients overexpressing the myc proto-oncogene via the 8; 14 translocation may have a favorable prognosis with shortterm intensive therapy.6 However, the incidence of each of these abnormalities is low. Overall, the translocations resulting in bcr-ab1 (3% to 5%), E2A-PBX1 (6%), MLL-AF4 (2%), and myc overexpression (1%) are rare.
Abnormalities of the p53 gene are common in human cancers and may be of prognostic significance in hematologic malignan~ies.~ The use of p53 as a potential prognostic marker in childhood ALL appears limited as the incidence of p53 mutations at diagnosis is low.' In a large retrospective study of 330 patients, only eight were found to have p53 gene mutations. Nevertheless, there is a suggestion that p53 mutations may be important in determining the response to therapy, because four of the eight patients with mutations died of aggressive disease. p53 mutations are uncommon in childhood T-cell ALL at diagnosis, but may be more frequently detected at relapse and can be a predictor of subsequent outcome.' can occur at the transcriptional and posttranscriptional level in primary leukemic cells. Although we were unable to link Waf-l RNA expression with p53 status in childhood ALL, our data show potential p53 inactivation by multiple mechanisms in a large percentage of these patients and demonstrate that these alterations can be detected at diagnosis. Inactivation of the p53 pathway may, therefore, be important in children with ALL who fail to respond to treatment and may be useful for the early identification of children requiring alternative therapies.
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Overexpression of mdm-2 constitutes a potential alternative mechanism of p53 pathway inactivation," but its significance has not been determined in pediatric ALL. Mdm-2 RNA overexpression is seen in about 20% to 30% of ALL."." Mdm-2 RNA overexpression is seen in all pediatric ALL cell lines where there was a wild type p53 gene present,13 but the significance of mdm-2 overexpression in primary leukemic cells at diagnosis remains unclear.
In this study, we examine p53 gene status and mdm-2 expression in the bone marrow mononuclear cells of 10 children with ALL who failed to achieve complete remission or who relapsed shortly after achieving remission ("poor outcome" ALL). Our goal was to determine whether molecular alterations in the p53 pathway through p53 gene mutations or mdm-2 protein overexpression were a frequent event in poor outcome pediatric ALL. We show that there is a high incidence of potential p53 pathway inactivation in this group of patients and that the alterations can be detected at diagnosis. Three patients demonstrated p53 gene mutations, while four other patients overexpressed mdm-2 protein. In addition, we describe two patients with mdm-2 protein over-expression who had normal mdm-2 RNA levels, indicating the importance of measuring protein and not just RNA and pointing to a novel posttranscriptional mechanism of mdm-2 overexpression in primary leukemic cells.
MATERIALS AND METHODS

Patients and samples.
Patients included in this study were treated on the Pediatric Oncology Group (POG) ALin C #l5 Studies for Standard and High Risk Acute Lymphoblastic Leukemia, conducted between January 1991 and November 1994. Informed consent for sample submission was obtained from patients or from their parents. Bone marrow specimens were routinely obtained from all patients at diagnosis entered onto these studies and were sent by overnight courier to the St Jude Children's Research Hospital. Mononuclear cells from these bone marrow specimens were separated by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) density gradient sedimentation, washed in phosphate-buffered saline, resuspended in 70% RPMI/20% fetal calf semm/lO% dimethyl sulfoxide, and cryopreserved in liquid nitrogen. We identified children on these studies who failed to achieve complete remission or who achieved complete remission, but developed relapse within 6 months of diagnosis and had cryopreserved cells available for study. Cryopreserved cells from these patients were sent by overnight courier in dry ice and were immediately thawed and processed. Lymphocytes from normal donors (obtained with informed consent) were also prepared by FicollHypaque density gradient sedimentation and were stored as described above.
Cytogenetic andfluorescent in situ hybridization analysis. Standard cytogenetic techniques were employed and at least 20 metaphases were examined on each patient where possible. Single color metaphase fluorescent in situ hybridization (FISH) was performed using a mixture of digoxigenin labelled p53 cosmid and labelled 17-alpha satellite probes (Oncor, Gaithersburg, MD). Hybridization, posthybridization washes, and detection with fluorescein isothiocyanate labelled antidigoxigenin antibody were performed according to the manufacturer's recommended conditions. DNA extraction, polymerase chain reaction single strand conformational polymorphism analysis and DNA sequencing. High molecular weight DNA was purified from ethanol after a proteinase K digestion and a phenol-chloroform extraction.I4 Polymerase chain reactions (PCR) were performed with p53 amplimer primers (exons 4-9, Clontech, Palo Alto, CA) using the manufacturer's recommended conditions. Labelled PCR products were then denatured, chilled on ice, and immediately loaded onto two gel systems to maximize the potential for observing mobility shifts.15 These were a 6% polyacrylamide/0.5~ TBE gel containing 5% glycerol'' and a mutation detection enhancement gel with 0.6X TBE (Hydrolink-MDE, AT Biochem, Malvern, PA). Products were electrophoresed at 25 W for 5 hours (or at 10 W for 14 hours for MDE gels) at room temperature, dried under vacuum, and subjected to autoradiography. Aberrant migrating bands were excised from dried gels, resuspended in water, boiled for 15 minutes, and reamplified with appropriate primer combinations. PCR products were then subcloned into PCRIII (Invitrogen, San Diego, CA). DNA from clones containing inserts was pooled and sequenced with a Sequenase I1 kit from US Biochemicals (Cleveland, OH) using the p53 amplimer primers.
Northern analysis. RNA was isolated using RNAzol-B (Biotecx, Houston, TX), and approximately 10 pg of total cellular RNA was blotted onto Hybond N' membrane (Amersham, Arlington Heights, IL) after separation on 1% formaldehyde-agarose gels.17 Blots were then hybridized with a random hexamer 32P-labelled mdm-2 probe" or Waf-l probe (a kind gift from W. El-Dheiry, University of Pennsylvania, Philadelphia, PA) in Rapidhyb buffer (Amersham) as per the manufacturer's instructions. Blots were subsequently washed once at room temperature with 2X SSC/O.l% sodium dodecyl sulfate (SDS) and then twice with 0.2X SSC/0. I% SDS at 65°C. Densitometry was performed with RFLP-scan software (Scanalytics, Laurel, MD), and relative overexpression of mdm-2 and Waf-l were determined after standardization with 18s RNA.
Western analysis. Western blot analysis with 100 pg of total cellular protein was performed with monoclonal antibodies to mdm-2 (IF2, Oncogene Sciences, San Diego, CA), p53 (DO-l, Oncogene Sciences) and actin (Amersham) as described previously." Verification of loading was also evaluated after transfer using Ponceau S (Sigma, St Louis, MO).
RESULTS
Patient characteristics, therapy, and survival. The major clinical and prognostic findings in the 10 patients treated on one of two POG protocols (900518 and 9006") are summarized in Table 1 . All individuals responded poorly to therapy and had short event-free survivals (median 39 days). Nine of 10 patients had at least one adverse prognostic feature. The majority were male, and five of 10 were younger than 2 or older than 10 years. Eight of 10 had a white cell count exceeding 50 X lo9& and four had extramedullary disease. Cytogenetic abnormalities were seen in 70%, but only one patient had involvement of chromosome 17. Two patients had a t(4;ll) and one had an atypical t(9;22); none had a t( 1 ; 19) rearrangement.
P53 gene status. Single strand conformational polymorphism (SSCP) has been used extensively to detect mutations within the p53 gene and has been shown to be >90% effective when analyzing PCR products between 100 and 300 bp long (reviewed in reference 20). We, therefore, employed this type of analysis to identify if any of the 10 poor outcome patients possessed mutations within the "hot spot" regions (exons 4 to 9) of p53 at diagnosis. Three patients (1, 6, and 10) had mobility shifts involving exons 8, 6, and 5 respectively (Fig 1) . Patients 6 and 10 appeared to possess wild type alleles in the analyzed cell population, while patient 1 had only mutant p53 alleles. DNA sequencing showed that patient 1 had a pro,arg insertion at AA282. This is within a "hot spot" region of p53 and is in an evolutionarily conserved domain, which is one of the most frequent sites of missense mutations. The second (patient 6) had an asp to gly substitution at AA207, which is not in an evolutionarily conserved site, but is close to a region of p53 that is recognized by a mutant conformation specific p53 monoclonal antibody.'" It is noteworthy that this patient, who did not respond to induction chemotherapy and developed progressive disease at 22 days, had no adverse clinical prognostic factors. The only patient (number 10) to have loss of heterozygosity for the p53 gene by karyotype analysis (Table 1) had a single nucleotide deletion (-C) at codon 179 resulting in a frameshift mutation. Karyotype analysis, but not SSCP, suggested loss of the other functional allele in malignant cells from patient 10. FISH analysis was performed to determine the p53 gene status in the malignant cell population from this patient (Fig 2) and demonstrated that this patient had two populations of cells. Approximately 50% of metaphases examined contained two chromosome 17s and two 
IO).
Mdm-2 RNA overexpression appears to be common in hematological malignancies and has been found in 20% to 50% of cases of AML and ALL."." Figure 3 shows a Northem blot of the IO pediatric ALL patients using RNA from samples obtained at diagnosis. Of IO patients analyzed by northern blots, two overexpressed mdm-2 RNA more than IO-fold compared with bone marrow cells from a normal donor.
Recent work in choriocarcinoma cell lines" and in primary leukemic cells from Sezary syndrome patients'' showed that mdm-2 proteins can be overexpressed in the absence of increased levels of mdm-2 transcripts. This underscores the need to analyze relative levels of mdm-2 proteins to fully evaluate mdm-2 overexpression in human cancers. Similar to control bone marrow cells, mdm-2 protein was barely detectable or not detectable in six of IO patients. However, four poor outcome patients had cells with elevated levels of mdm-2 protein (Fig 4) . Interestingly, two of these four patients had normal levels of mdm-2 RNA. Also, multiple mechanisms of overexpression may play a role in patients with elevated levels of mdm-2 RNA as the extent of mdm-2 protein overexpression was much greater than the extent of mdm-2 RNA overexpression. All of the patients with mdm-2 protein overexpression had wild type p53 genes, but only four of the seven patients with wild type p53 had mdm-2 overexpression.
Meas~rrement of Wqf-1 RNA levels. It is not certain which p53 gene mutations or what degree of mdm-2 overexpression is necessary to cause p53 pathway inactivation in vivo. Waf-I is a gene that is transcriptionally upregulated by wild type and not mutant p53 (reviewed in reference 22). For these reasons we chose to analyze Waf-l RNA as a potential downstream marker of p53 pathway activity in primary leukemic cells. Normal bone marrow had relatively low levels of Waf-l RNA (Fig 5) . There was a wide range in Waf-l RNA levels in the 10 samples. Patient 1, who has a p53 mutation, had low Waf-l RNA levels, but patients 6 and 10, who also have p53 mutations, had relatively high levels. Overall, in a small group of patients, there was no significant difference in Waf-l RNA levels between the patients with p53 or mdm-2 abnormalities and those without.
DISCUSSION
The p53 pathway is potentially affected by p53 gene mutation or mdm-2 overexpression in a wide variety of human cancers. The presence of p53 mutations appears to confer a worse prognosis in some20*23-25 but not all types of solid tumorsF6 Similar to solid tumors, the significance of p53 mutations in hematologic malignancies depends on the precise diagnosis. For example, in a large retrospective study of acute myeloid leukemia, myelodysplastic syndrome, and chronic lymphocytic leukemia, p53 mutations were found to correlate with low complete remission rates and poor survival? However, the presence of p53 mutations did not confer a worse prognosis in Burkitt's lymphoma." Although mdm-2 overexpression has been associated with poor prognostic features in small series of patients with diverse hematologic malignancies,".'2 the overall significance of mdm-2 overexpression in leukemia is uncertain.
With the exception of L3
abnormalities of the p53 pathway appear to be uncommon in pediatric ALL: occurring in less than 3% of all patients. This finding seems to suggest that abnormalities of the p53 pathway are unlikely to be a significant prognostic factor in this disease. Alternatively, p53 may be important prognostically, but inactivation may occur through mechanisms other than p53 gene mutation. This study of 10 poor outcome children with ALL demonstrates that p53 inactivation may be a consistent and common molecular abnormality at diagnosis in pediatric ALL patients who fail to enter complete remission or relapse soon after achieving remission. Abnormalities of the p53 pathway through p53 gene mutations (three patients) or mdm-2 overexpression (four patients) were seen in seven of 10 individuals. It is likely that these alterations may be restricted to poor outcome patients. This is based on studies by others demonstrating that p53 gene mutations are rare in unselected cases of pediatric ALL: but are much more common in samples taken from patients at the time of relapse? Also, in an initial screen of 25 good outcome patients, we were unable to identify any patients who overexpressed mdm-2 (Marks, Kurz and Haines, unpublished data). Confirmation that p53 pathway alterations are important in the response of this disease to chemotherapy will require a study that compares poor outcome ALL to a group of good outcome patients who respond well to therapy and remain in long-term continuous remission.
It is becoming apparent that p53 mutations may have variable effects on cellular proliferation." Some p53 mutants Mdm-2 Northern analysis, using RNA isolated from bone marrow lymphocytes of 10 children with poor outcome ALL at diagnosis and from the marrow of one normal donor (NI, was performed as described in Materials and Methods. The relative levels of mdm-2 RNA, mdm-Z(N), for each patient were determined by densitometric analysis after normalization for loading differences with 18s RNA.
may have dominant negative activity,."'.." while for other mutations, complete p53 pathway inactivation may require alteration of both alleles." Two of the patients demonstrated both loss of heterozygosity for p53 and a p53 gene mutation, while one patient with a p53 mutation appeared to have retained one wild-type allele. It is possible that the p53 pathway is functional in this last individual. Another major uncertainty when assessing p53 pathway function is what degree of mdm-2 overexpression is necessary to inhibit p53 activity. These observations highlight the importance of assessing p53 pathway function in vivo. It may be possible to use downstream transcriptional targets of p53 as a method of assessing p53 function. Unfortunately, our data show no statistically significant difference between the levels of Waf-1 RNA (a gene that is upregulated by wild type and not mutant p53) in individuals with p53 pathway abnormalities compared with those with wild type p53 alleles and normal mdm-2 levels. This was not a surprising finding as other investigators have shown that Waf-l may be regulated by p53 independent mechanisms in leukemic celk3" Other p53 transcriptional need to be analyzed in these pa- Waf-l Northern analysis, using RNA isolated from bone marrow lymphocytes of 10 children with poor outcome ALL at diagnosis and from the marrow of one normal donor (NI, was performed as described in Materials and Methods. The relative levels of Waf-l RNA, Waf-l (NI, for each patient were determined by densitometric analysis after normalization for loading differences with 18s RNA.
tients to determine if this type of analysis will prove to be a valid way of assessing p53 function in primary tumor cells.
In keeping with previous studies of cell lines derived from pediatric ALL patients," all individuals with mdm-2 overexpression had wild type p53 alleles. Also, the same study showed that all lines that had wild type alleles overexpressed mdm-2. We were unable to demonstrate either mdm-2 RNA or protein overexpression in three patients with wild type p53 alleles. It is, therefore, unlikely that mdm-2 overexpression in leukemic cells with wild type p53 is simply due to the increased proliferative potential of these cells in vivo.
This study also shows that mdm-2 overexpression can occur in the absence of increased mdm-2 RNA in primary leukemic cells. Two patients had elevated levels of both mdm-2 RNA and mdm-2 protein, while two patients had only elevated levels of mdm-2 protein. This finding emphasizes the importance of measuring mdm-2 protein and not only mdm-2 RNA when evaluating the incidence of mdm-2 overexpression in hematological malignancies. It also demonstrates that mdm-2 overexpression can occur at both transcriptional and posttranscriptional levels. It is supported by our data showing that the relative levels of mdm-2 protein 1, 6, 7, 8, or 9 . Low levels of mdm-2 protein were observed for patient 10. The number presented represents the relative intensity of the mdm-2 band. The apparent band for patient 7 represents a blotting error; no mdm-2 protein was detectable on repeated experiments.
For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From overexpression is greater than the relative levels of mdm-2 RNA overexpression in patients with increased mdm-2 RNA. Recent work has proposed that the posttranscriptional mechanism of enhanced translation can cause mdm-2 overexpression in a human choriocarcinoma cell line." Studies measuring translation efficiency of mdm-2 RNA and mdm-2 protein stability are currently being performed to determine the mechanism of mdm-2 overexpression in leukemic cells. We have recently documented mdm-2 protein overexpression in the absence of mdm-2 RNA overexpression in Sezary syndrome." These mechanistic studies will be important for elucidating the regulation of mdm-2 expression in normal lymphocytes and for determining the cause of altered expression in leukemia.
